IL154350A0 - New phenylalanine derivatives - Google Patents

New phenylalanine derivatives

Info

Publication number
IL154350A0
IL154350A0 IL15435001A IL15435001A IL154350A0 IL 154350 A0 IL154350 A0 IL 154350A0 IL 15435001 A IL15435001 A IL 15435001A IL 15435001 A IL15435001 A IL 15435001A IL 154350 A0 IL154350 A0 IL 154350A0
Authority
IL
Israel
Prior art keywords
phenylalanine derivatives
new phenylalanine
integrin
chem
alpha
Prior art date
Application number
IL15435001A
Other languages
English (en)
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of IL154350A0 publication Critical patent/IL154350A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15435001A 2000-08-18 2001-08-15 New phenylalanine derivatives IL154350A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000248728 2000-08-18
JP2001147451 2001-05-17
PCT/JP2001/007039 WO2002016329A1 (fr) 2000-08-18 2001-08-15 Nouveaux derives de phenylalanine

Publications (1)

Publication Number Publication Date
IL154350A0 true IL154350A0 (en) 2003-09-17

Family

ID=26598103

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15435001A IL154350A0 (en) 2000-08-18 2001-08-15 New phenylalanine derivatives
IL154350A IL154350A (en) 2000-08-18 2003-02-09 Phenylalanine derivatives and pharmaceutical preparations containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL154350A IL154350A (en) 2000-08-18 2003-02-09 Phenylalanine derivatives and pharmaceutical preparations containing them

Country Status (27)

Country Link
US (4) US7153963B2 (sk)
EP (1) EP1288205B1 (sk)
JP (1) JP3440469B2 (sk)
KR (1) KR100675036B1 (sk)
CN (1) CN1325480C (sk)
AT (1) ATE497385T1 (sk)
AU (2) AU2001278740B9 (sk)
BG (1) BG66085B1 (sk)
BR (1) BRPI0113331B8 (sk)
CA (1) CA2420040C (sk)
CZ (1) CZ302653B6 (sk)
DE (1) DE60143984D1 (sk)
DK (1) DK1288205T3 (sk)
HU (1) HU228914B1 (sk)
IL (2) IL154350A0 (sk)
MX (1) MXPA03001495A (sk)
NO (1) NO325738B1 (sk)
NZ (1) NZ524122A (sk)
PL (1) PL223152B1 (sk)
PT (1) PT1288205E (sk)
RU (1) RU2286340C2 (sk)
SI (1) SI1288205T1 (sk)
SK (1) SK287781B6 (sk)
TW (1) TWI229077B (sk)
UA (1) UA74385C2 (sk)
WO (1) WO2002016329A1 (sk)
YU (1) YU12203A (sk)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
PL223152B1 (pl) * 2000-08-18 2016-10-31 Ajinomoto Kk Pochodne fenyloalaniny, kompozycja farmaceutyczna oraz zastosowanie tych pochodnych
DE60124573T2 (de) 2000-09-29 2007-06-21 Ajinomoto Co., Inc. Neue phenylalanin-derivate
JP4164871B2 (ja) * 2001-07-26 2008-10-15 味の素株式会社 新規フェニルプロピオン酸誘導体
EP1454898A4 (en) 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
JP4470219B2 (ja) 2002-02-20 2010-06-02 味の素株式会社 新規フェニルアラニン誘導体
WO2004074264A1 (ja) 2003-02-20 2004-09-02 Ajinomoto Co., Inc. キナゾリンジオン骨格を有するフェニルアラニン誘導体の製造方法及び製造中間体
EP3216449A1 (en) * 2003-11-14 2017-09-13 EA Pharma Co., Ltd. Oral administration preparation of phenylalanine derivatives
CA2546115C (en) * 2003-11-14 2013-01-08 Ajinomoto Co., Inc. Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives
CA2547625C (en) 2003-11-27 2012-07-24 Ajinomoto Co., Inc. Crystals of phenylalanine derivatives and production methods thereof
JP4743659B2 (ja) 2003-12-22 2011-08-10 味の素株式会社 新規フェニルアラニン誘導体
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
WO2005117978A2 (en) * 2004-06-04 2005-12-15 Genentech, Inc. Method for treating multiple sclerosis
PA8635501A1 (es) * 2004-06-04 2006-06-02 Genentech Inc Uso de un anticuerpo para el tratamiento del lupus
WO2006137450A1 (ja) * 2005-06-21 2006-12-28 Ajinomoto Co., Inc. フェニルアラニン誘導体の結晶、その製造方法及びその使用
CN101360736A (zh) * 2005-11-23 2009-02-04 阿斯利康(瑞典)有限公司 L-丙氨酸衍生物
CN103265495B (zh) * 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
TW200808731A (en) * 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
AR060901A1 (es) 2006-05-12 2008-07-23 Jerini Ag Compuestos heterociclicos para la inhibicion de integrinas y uso de estos
JP2009539815A (ja) * 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
ATE556061T1 (de) * 2006-06-19 2012-05-15 Toray Industries Therapeutisches oder prophylaktisches mittel gegen multiple sklerose
ATE497761T1 (de) * 2006-06-20 2011-02-15 Toray Industries Therapeutisches oder prophylaktisches mittel gegen leukämie
RU2469028C2 (ru) 2006-11-22 2012-12-10 Адзиномото Ко., Инк. Способ получения производных фенилаланина с хиназолиндионовым скелетом и промежуточных соединений, применяемых при получении таких производных
US20090062267A1 (en) * 2007-01-29 2009-03-05 Astrazeneca Ab L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
EA022201B1 (ru) 2008-04-11 2015-11-30 Мерримак Фармасьютикалз, Инк. Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2554542B1 (en) 2010-03-29 2015-10-07 Ajinomoto Co., Inc. Phenylalanine derivative hydrochloride salt crystal
CN106963741A (zh) 2010-03-29 2017-07-21 Ea制药株式会社 含有苯基丙氨酸衍生物的医药制剂
EP2769223A1 (en) 2011-10-17 2014-08-27 Westfälische Wilhelms-Universität Münster Assessment of pml risk and methods based thereon
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
WO2013116287A1 (en) 2012-01-31 2013-08-08 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
EP2842945B1 (en) 2012-04-24 2016-10-26 EA Pharma Co., Ltd. Sulfonamide derivative and medicinal use thereof
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
BR112015031040A8 (pt) * 2013-06-11 2018-01-02 Receptos Inc Novos moduladores do receptor de glp-1
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
WO2015064580A1 (ja) * 2013-10-29 2015-05-07 味の素株式会社 スルホンアミド誘導体及びその医薬用途
MX2017003780A (es) * 2014-09-29 2017-06-30 Ea Pharma Co Ltd Composicion farmaceutica para tratar colitis ulcerativa.
US10307535B2 (en) 2014-12-19 2019-06-04 Medtronic Minimed, Inc. Infusion devices and related methods and systems for preemptive alerting
CA2981371A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
KR20180075537A (ko) 2015-10-06 2018-07-04 제넨테크, 인크. 다발성 경화증을 치료하기 위한 방법
US10562898B2 (en) 2016-02-05 2020-02-18 Ea Pharma Co., Ltd. Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US11963996B2 (en) * 2018-10-24 2024-04-23 Orthotrophix, Inc. Method of treating knee pain
JP7192139B2 (ja) 2018-10-30 2022-12-19 ギリアード サイエンシーズ， インコーポレイテッド α４β７インテグリン阻害剤としてのキノリン誘導体
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2022072156A1 (en) 2020-10-01 2022-04-07 Orthotrophix, Inc. Hard tissue therapeutics

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2419928A1 (fr) 1978-03-15 1979-10-12 Metabio Joullie Sa Nouveaux derives de la n-phenylalanine, leur preparation et leur application comme medicaments
DE4111394A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
HU914U (en) 1995-04-19 1996-10-28 Koevesi Machine tool for contour turning
IL130900A0 (en) 1997-02-28 2001-01-28 Pfizer Prod Inc Atropisomers of 3-aryl-4(3H)- quinazolinones and their use as ampa-receptor antagonsts
BR9811594A (pt) * 1997-07-31 2000-09-05 Elan Pharm Inc Compostos de dipeptìdeo sulfonilados que inibem adesão de leucócito mediada por vla-4
JP2001512134A (ja) 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Ｖｌａ−４仲介性白血球付着を阻害する置換フェニルアラニン型化合物
AU742928C (en) 1997-08-22 2003-02-20 F. Hoffmann-La Roche Ag N-alkanoylphenylalanine derivatives
RU2220950C2 (ru) * 1997-08-22 2004-01-10 Ф.Хоффманн-Ля Рош Аг N-алканоилфенилаланиновые производные
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
JP2002504534A (ja) 1998-02-26 2002-02-12 セルテック・セラピューティクス・リミテッド α４インテグリンの阻害剤としてのフェニルアラニン誘導体
GB2354440A (en) 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
DE60033684T2 (de) 1999-11-18 2007-12-06 Ajinomoto Co., Inc. Phenylalaninderivate
CA2392566A1 (en) 1999-12-06 2001-06-14 F. Hoffmann-La Roche Ag 4-pyridinyl-n-acyl-l-phenylalanines
BR0016195A (pt) 1999-12-06 2002-08-13 Hoffmann La Roche 4-pirimidinil-n-acil-l-fenilalaninas
JP4784803B2 (ja) 1999-12-28 2011-10-05 味の素株式会社 新規フェニルアラニン誘導体
WO2001070670A1 (fr) 2000-03-23 2001-09-27 Ajinomoto Co., Inc. Nouveau derive de phenylalanine
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
PL223152B1 (pl) 2000-08-18 2016-10-31 Ajinomoto Kk Pochodne fenyloalaniny, kompozycja farmaceutyczna oraz zastosowanie tych pochodnych
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
DE60124573T2 (de) 2000-09-29 2007-06-21 Ajinomoto Co., Inc. Neue phenylalanin-derivate
JP4164871B2 (ja) 2001-07-26 2008-10-15 味の素株式会社 新規フェニルプロピオン酸誘導体
EP1454898A4 (en) 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
JP4470219B2 (ja) 2002-02-20 2010-06-02 味の素株式会社 新規フェニルアラニン誘導体
WO2004074264A1 (ja) 2003-02-20 2004-09-02 Ajinomoto Co., Inc. キナゾリンジオン骨格を有するフェニルアラニン誘導体の製造方法及び製造中間体
CA2547625C (en) 2003-11-27 2012-07-24 Ajinomoto Co., Inc. Crystals of phenylalanine derivatives and production methods thereof
JP4743659B2 (ja) 2003-12-22 2011-08-10 味の素株式会社 新規フェニルアラニン誘導体
WO2006137450A1 (ja) 2005-06-21 2006-12-28 Ajinomoto Co., Inc. フェニルアラニン誘導体の結晶、その製造方法及びその使用

Also Published As

Publication number Publication date
MXPA03001495A (es) 2003-06-06
US20030220268A1 (en) 2003-11-27
PL223152B1 (pl) 2016-10-31
US8222405B2 (en) 2012-07-17
US20060223836A1 (en) 2006-10-05
YU12203A (sh) 2006-03-03
NO325738B1 (no) 2008-07-14
HU228914B1 (hu) 2013-06-28
BR0113331A (pt) 2004-02-25
CA2420040A1 (en) 2003-02-18
SI1288205T1 (sl) 2011-05-31
KR100675036B1 (ko) 2007-01-29
US7153963B2 (en) 2006-12-26
AU2001278740B9 (en) 2006-09-28
CA2420040C (en) 2009-02-03
TWI229077B (en) 2005-03-11
BG107555A (bg) 2003-09-30
US8426588B2 (en) 2013-04-23
AU7874001A (en) 2002-03-04
BR0113331B1 (pt) 2017-11-14
US20120253041A1 (en) 2012-10-04
BRPI0113331B8 (pt) 2021-05-25
CN1469867A (zh) 2004-01-21
PL361383A1 (en) 2004-10-04
JP3440469B2 (ja) 2003-08-25
NO20030744L (no) 2003-04-07
KR20030048011A (ko) 2003-06-18
US7872125B2 (en) 2011-01-18
CZ302653B6 (cs) 2011-08-17
EP1288205B1 (en) 2011-02-02
IL154350A (en) 2010-02-17
CN1325480C (zh) 2007-07-11
UA74385C2 (uk) 2005-12-15
HUP0302997A3 (en) 2004-03-29
SK287781B6 (sk) 2011-09-05
PT1288205E (pt) 2011-05-06
NO20030744D0 (no) 2003-02-17
NZ524122A (en) 2005-02-25
WO2002016329A1 (fr) 2002-02-28
EP1288205A4 (en) 2007-05-23
US20110065918A1 (en) 2011-03-17
BG66085B1 (bg) 2011-03-31
HUP0302997A2 (hu) 2004-01-28
AU2001278740B2 (en) 2006-04-06
CZ2003481A3 (cs) 2003-06-18
ATE497385T1 (de) 2011-02-15
DE60143984D1 (de) 2011-03-17
EP1288205A1 (en) 2003-03-05
RU2286340C2 (ru) 2006-10-27
SK1912003A3 (en) 2003-07-01
DK1288205T3 (da) 2011-05-23

Similar Documents

Publication Publication Date Title
IL154350A0 (en) New phenylalanine derivatives
EP1233013A4 (en) phenylalanine derivatives
EP1477482A4 (en) NEW PHENYLALANINE DERIVATIVE
EP2615087A3 (en) Phenylalanine derivatives
HUP0401567A3 (en) Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
GEP20074099B (en) 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
HK1052343A1 (zh) 作為α4整聯蛋白拮抗劑的氮雜-橋連-雙環氨基酸衍生物
BG106586A (en) Pyrazolopyramidines as therapeutic agents
HUP0200308A2 (en) Quinolinecarboxamides as antiviral agents, pharmaceutical compositions containing them and their use
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
GB0004167D0 (en) 1-piperidinyl-propan-2-ol derivatives and their use as therapeutic agents
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
DK1421094T3 (da) 4" deoxy 4" (S) aminoavermectinderivater
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
SE9902742D0 (sv) New pharmaceutical formultion
PL375197A1 (en) Novel adenosine analogues and their use as pharmaceutical agents
AU2002322424A8 (en) Novel methods and formulations for administration of active agents
GB9926138D0 (en) Diphenylacetic acid derivatives and their use as antiviral agents
AU2002211817A1 (en) Treatment of swine's anemia and low weight
AU2001251462A1 (en) Compositions and methods for detection of von willebrand's disease
ITRM20000624A0 (it) Uso di derivati dell'acidocinnamico come agenti insetticidi.
AU2002348042A1 (en) 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
UA3710S (uk) Сидіння ортопедичне "кіпарис"
UA3098S (uk) Стілець "ризький"
IT250752Y1 (it) Tavola sterilizzatrice per bide'